Adverse events associated with transfusion · People with a haematological disorder
1 finding from 1 review
Quality of life ‐ not reported · People with a haematological disorder
1 finding from 1 review
Treatment failure · Patients with presumed drug‐sensitive TB
1 finding from 1 review
Relapse · Patients with presumed drug‐sensitive TB
1 finding from 1 review
Death from any cause · Patients with presumed drug‐sensitive TB
It is very uncertain whether fluoroquinolone plus standard regimen changes death from any cause compared with standard regimen alone (very low certainty).
1 finding from 1 review
TB‐related death · Patients with presumed drug‐sensitive TB
It is very uncertain whether fluoroquinolone plus standard regimen changes TB‐related death compared with standard regimen alone (very low certainty).
1 finding from 1 review
Sputum culture conversion at 8 weeks · Patients with presumed drug‐sensitive TB
It is very uncertain whether fluoroquinolone plus standard regimen changes sputum culture conversion at 8 weeks compared with standard regimen alone (very low certainty).
1 finding from 1 review
Serious adverse events · Patients with presumed drug‐sensitive TB
It is very uncertain whether fluoroquinolone plus standard regimen changes serious adverse events compared with standard regimen alone (very low certainty).
1 finding from 1 review
One or more adverse event · Patients with presumed drug‐sensitive TB
It is very uncertain whether fluoroquinolone plus standard regimen changes one or more adverse event compared with standard regimen alone (very low certainty).
1 finding from 1 review
Overall survival (reported as mortality) · high‐risk neuroblastoma patients treated with autologous HSCT
Retinoic acid postconsolidation therapy showed no clear difference in overall survival (reported as mortality) compared with no further treatment (low certainty).
1 finding from 1 review
Treatment‐related mortality ‐ not reported · high‐risk neuroblastoma patients treated with autologous HSCT
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Progression‐free survival ‐ not reported · high‐risk neuroblastoma patients treated with autologous HSCT
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Event‐free survival · high‐risk neuroblastoma patients treated with autologous HSCT
Retinoic acid postconsolidation therapy showed no clear difference in event‐free survival (reported as relapse, disease progression, death… compared with no further treatment (low certainty).
1 finding from 1 review
Early toxicity ‐ not reported · high‐risk neuroblastoma patients treated with autologous HSCT
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Late toxicity including secondary malignancies ‐ not reported · high‐risk neuroblastoma patients treated with autologous HSCT
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life ‐ not reported · high‐risk neuroblastoma patients treated with autologous HSCT
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Absence of nausea ( · people with chemotherapy‐induced nausea and vomiting
It is very uncertain whether cannabinoid plus other anti‐emetic agent changes absence of nausea ( compared with other anti‐emetic monotherapy (very low certainty).
1 finding from 1 review
Absence of vomiting ( · people with chemotherapy‐induced nausea and vomiting
Cannabinoid plus other anti‐emetic agent showed no clear difference in absence of vomiting ( compared with other anti‐emetic monotherapy (low certainty).
1 finding from 1 review
Absence of nausea and vomiting ( · people with chemotherapy‐induced nausea and vomiting
Cannabinoid plus other anti‐emetic agent showed no clear difference in absence of nausea and vomiting ( compared with other anti‐emetic monotherapy (low certainty).
1 finding from 1 review
Withdrawal for any reason (medium term: treatment duration from 5 to 8 weeks) · people with chemotherapy‐induced nausea and vomiting
Cannabinoid plus other anti‐emetic agent showed no clear difference in withdrawal any reason ( compared with other anti‐emetic monotherapy (low certainty).
1 finding from 1 review